Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

NCT05067335 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT05067335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05067335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Completed
Start date
October 21, 2021
Completion date
November 9, 2023
Enrollment
327 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis